We are live on ! Find out more
BOLD

Audentes Therapeutics, Inc
BOLD

Delisted

BOLD was delisted on the 14th of January, 2020.

0 hedge funds and large institutions have $0 invested in Audentes Therapeutics, Inc in 2020 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 186 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 1880 (-188)

100% less funds holding in top 10

Funds holding in top 10: 190 (-19)

100% less capital invested

Capital invested by funds: $2.57B → $0 (-$2.57B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 186

Holders
Holders Change
-188
Holders Change %
-100%
% of All Funds
Holding in Top 10
Holding in Top 10 Change
-19
Holding in Top 10 Change %
-100%
% of All Funds
New
Increased
Reduced
Closed
186
Calls
Puts
Net Calls
Net Calls Change

BOLD Hedge Fund Activity: Q1 2020 in Review

0 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Audentes Therapeutics, Inc (BOLD) for Q1 2020, worth a combined $0 — down 100% from $2.57B a quarter earlier.

Sellers outnumbered buyers: 186 funds closed out of BOLD and 0 opened new positions — a net loss of 186 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was BlackRock, exiting entirely with an estimated $220M sold.

  • 0 institutional investors held Audentes Therapeutics, Inc (BOLD) as of Q1 2020, down from 188 in Q4 2019.
  • Funds reported $0 of Audentes Therapeutics, Inc stock for Q1 2020, down 100% quarter-over-quarter.
  • 0 funds opened new Audentes Therapeutics, Inc positions in Q1 2020 and 186 closed out, a net change of -186 holders.
  • The largest Audentes Therapeutics, Inc seller in Q1 2020 was BlackRock, an estimated $220M sold.

Based on aggregated 13F filings for Q1 2020.